Timothy Anderson of Prudential Equities, who has an "overweight" rating on Wyeth, pointed to a number of potential pitfalls in a note this morning.

FORBES: Wyeth's Blowout Quarter

In a report last week, Tim Anderson, a sell-side analyst at Prudential Equities group, predicted that the Premarin trial would be ending early (see " Wyeth's Premarin Trial Seen Ending Early").

FORBES: Wyeth Lucks Out On Hormone Study

In a note to investors this morning, Prudential Equities analyst Timothy Anderson wrote that he is unconvinced about the benefits of scale for drugmakers like Novartis and Pfizer (nyse: PFE - news - people ).

FORBES: If Novartis Steps In, Will Pfizer Follow?

On Monday, Tim Anderson, a sell-side analyst at Prudential Equities, wrote in a research note that he and his team believe that Bristol carefully designed Prove-It to show the drugs are the same, perhaps by making the study too small or too short.

FORBES: Bristol Prepares Shot In Statin War